- Associated Press•31 minutes ago
The latest on developments in global financial markets (all times local): 4:00 p.m. More declines in health care stocks are pulling indexes lower on Wall Street. Biotechnology companies continued to fall ...
- Moody's•2 hours agoTeva Pharmaceutical Industries Ltd -- Moody's: Teva's Loss of Two Copaxone Patents is Credit Negative
New York, August 25, 2016-- Moody's Investors Service commented that the Patent Trial and Appeal Board's invalidation of two of Teva's patents on Copaxone 40 mg is credit negative. However, there is no ...
- Barrons.com•3 hours ago
While fundamentals of the group appear stable following the recent 2Q16 earnings season (see our recent note here) and valuations are attractive, we acknowledge that ongoing negative headlines may stunt the fledgling “recovery” that has started to take place in the space over the past couple of months. More broadly, while media scrutiny/political headlines around drug pricing could result in continued volatility through the elections, we continue to see the group positioned for a recovery over time, with valuations inexpensive on almost any metric (~8x 2017 EPS) and improving fundamentals after a challenging 1H/16.
Allergan plc (AGN)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||236.51 x 100|
|Ask||237.10 x 400|
|Day's Range||232.10 - 244.27|
|52wk Range||195.50 - 322.68|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||22.50|
|Avg Vol (3m)||3,123,604|
|Dividend & Yield||N/A (N/A)|